Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
215 Leser
Artikel bewerten:
(0)

JDRF Comments on New Data from the SEARCH for Diabetes in Youth Study Showing a 21 Percent Increase in Type 1 Diabetes Among American Youth

NEW YORK, May 3, 2014 /PRNewswire-USNewswire/ --Richard Insel, M.D., chief scientific officer of JDRF, issued the following statement today in response to a new study showing an increase in type 1 diabetes (T1D) among young people in the United States. According to the latest SEARCH for Diabetes in Youth Study data by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH), the prevalence of T1D in people under age 20 years rose by 21 percent between 2001 and 2009.

Statement:

"The new SEARCH for Diabetes in Youth Study data showing a 21 percent increase in the prevalence of type 1 diabetes among children and teens over eight years highlights the crucial need for research into ways to better manage and, ultimately, prevent and cure this life-threatening disease. The data confirm what JDRF and many public health experts have long suspected: The incidence of type 1 diabetes is on the rise in youth across all ethnic groups in the United States, and the disease is now having a more significant impact on black and Hispanic youth populations, which previously had relatively low rates of the disease.

"As the study's authors noted, the increased prevalence of type 1 diabetes among a more diverse population of children and teens is also of concern since minority youth have historically experienced poor glycemic control, which is known to be associated with diabetic complications. The broadening impact of this disease is among the many reasons that JDRF is committed to delivering therapies that help keep people with type 1 diabetes healthy and safe now while we work towards a cure.

"The SEARCH study also underlines the need for continued support of programs like the federal Special Diabetes Program, which provided funding for this study and also funds crucial basic research into the causes and mechanisms of type 1 diabetes, as well as efforts to cure, treat, and prevent it.

"Type 1 diabetes creates a serious health and financial burden for people with the disease and their families. The day-to-day need to measure blood-sugar levels, take insulin, and watch every bite of food is particularly daunting for children and teens, and it is a burden that JDRF is committed to ending through our sustained leadership in type 1 diabetes research."

About the SEARCH Study
SEARCH is the largest surveillance effort of diabetes among youth under the age of 20 years conducted in the United States to date. The study covers five clinical centers located in California, Colorado, Ohio, South Carolina, and Washington.

The SEARCH study is jointly funded by the Division of Diabetes Translation at the CDC and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the NIH, with resources from the government-funded Special Diabetes Program (SDP), which will expire if not renewed by Congress.

About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. As the largest charitable supporter of T1D research, JDRF is currently funding $568 million in scientific research in 17 countries. For more information, please visitjdrf.org.

Contact:
Shawn Rhea, (212) 479-7510; srhea@jdrf.org

SOURCE JDRF

© 2014 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.